Travere Therapeutics, Inc. (TVTX) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Eric M Dube

Chief Executive Officer

—

$13.12M (3) scheduled

−$13.12M

432,886

0.4592%

$23.82M

+19.6%

Peter Heerma

EVP, Chief Commercial Officer

—

117,066

0.1242%

$6.44M

+7.1%

Elizabeth E Reed

Chief Legal Officer and GC

—

105,389

0.1118%

$5.80M

+31.2%

Jula Inrig

EVP, Head of R&D & CMO

—

100,491

0.1066%

$5.53M

+62.2%

William E. Rote

Chief Research Officer

—

98,197

0.1042%

$5.40M

+12.8%

Jeffrey A Meckler

Director

—

91,500

0.0971%

$5.03M

+13.0%

Christopher R. Cline

Chief Financial Officer

—

87,508

0.0928%

$4.81M

+17.3%

Gary A Lyons

Director

—

61,500

0.0652%

$3.38M

+20.6%

Timothy Coughlin

Director

—

56,250

0.0597%

$3.09M

+14.8%

Sandra Calvin

SVP, Chief Accounting Officer

—

42,353

0.0449%

$2.33M

−18.6%

Roy D. Baynes

Director

—

41,500

0.0440%

$2.28M

+33.9%

Ron Squarer

Director

—

39,375

0.0418%

$2.17M

+36.4%

John A Orwin

Director

—

39,375

0.0418%

$2.17M

+36.4%

Sandra Poole

Director

—

34,000

0.0361%

$1.87M

+44.7%

Suzanne Louise Bruhn

Director

—

32,750

0.0347%

$1.80M

+47.2%

Brinkley Ruth Williams

Director

—

29,750

0.0316%

$1.64M

+54.5%

Travere Therapeutics, Inc.

What the insiders did Scheduled selling only

By person